Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1986 Dec;56(6):509–517. doi: 10.1136/hrt.56.6.509

Effect of the specific thromboxane receptor blocking drug AH23848 in patients with angina pectoris.

D P De Bono, P Lumley, M Been, R Keery, S E Ince, D F Woodings
PMCID: PMC1216397  PMID: 2948534

Abstract

The effect of the specific thromboxane receptor blocking drug AH23848 was investigated in two double blind placebo controlled studies in male patients with exercise induced angina pectoris and angiographically verified coronary lesions. In the first study cardiac pacing was performed in twenty patients after coronary angiography. Patients were then randomised into two groups and received either AH23848 (70 mg orally) or placebo. One hour later cardiac pacing was repeated. Neither treatment had any significant effect upon time to angina or the rate-pressure product at the onset of chest pain in these patients. In the second study twenty male patients were randomised to seven days' treatment with AH23848 (70 mg three times a day) or placebo followed by a crossover to the other treatment for a further seven days. Clinical assessment was performed before treatment and at the end of each treatment period. There was no significant difference between the placebo and AH23848 treatment periods in exercise tolerance, the rate-pressure product at angina after exercise testing, the number of ischaemic attacks as determined from 24 hour ambulatory electrocardiograms, the number of attacks of pain, or the number of glyceryl trinitrate tablets consumed. This lack of a clinical effect with AH23848 was seen despite a profound inhibition of ex vivo platelet aggregation stimulated by the thromboxane A2-mimetic U-46619. Because in experimental animals in vivo AH23848 blocks vascular thromboxane receptors as well as platelet thromboxane receptors the lack of effect of AH23848 in cardiac pacing and exercise induced angina is unlikely to be the result of inadequate blockade of thromboxane receptors. The lack of effect of the drug is more likely to indicate that thromboxane A2, is not a factor in the aetiology of the pain experienced by these patients during exercise or cardiac pacing.

Full text

PDF
509

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brittain R. T., Boutal L., Carter M. C., Coleman R. A., Collington E. W., Geisow H. P., Hallett P., Hornby E. J., Humphrey P. P., Jack D. AH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2. Circulation. 1985 Dec;72(6):1208–1218. doi: 10.1161/01.cir.72.6.1208. [DOI] [PubMed] [Google Scholar]
  2. Bruce R. A., McDonough J. R. Stress testing in screening for cardiovascular disease. Bull N Y Acad Med. 1969 Dec;45(12):1288–1305. [PMC free article] [PubMed] [Google Scholar]
  3. Chierchia S., de Caterina R., Crea F., Patrono C., Maseri A. Failure of thromboxane A2 blockade to prevent attacks of vasospastic angina. Circulation. 1982 Oct;66(4):702–705. doi: 10.1161/01.cir.66.4.702. [DOI] [PubMed] [Google Scholar]
  4. Coker S. J., Parratt J. R. AH23848, a thromboxane antagonist, suppresses ischaemia and reperfusion-induced arrhythmias in anaesthetized greyhounds. Br J Pharmacol. 1985 Sep;86(1):259–264. doi: 10.1111/j.1476-5381.1985.tb09457.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coker S. J., Parratt J. R., Ledingham I. M., Zeitlin I. J. Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature. 1981 May 28;291(5813):323–324. doi: 10.1038/291323a0. [DOI] [PubMed] [Google Scholar]
  6. Coleman R. A., Humphrey P. P., Kennedy I., Levy G. P., Lumley P. Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br J Pharmacol. 1981 Jul;73(3):773–778. doi: 10.1111/j.1476-5381.1981.tb16814.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ellis E. F., Oelz O., Roberts L. J., 2nd, Payne N. A., Sweetman B. J., Nies A. S., Oates J. A. Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A2. Science. 1976 Sep 17;193(4258):1135–1137. doi: 10.1126/science.959827. [DOI] [PubMed] [Google Scholar]
  8. FitzGerald G. A., Pedersen A. K., Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation. 1983 Jun;67(6):1174–1177. doi: 10.1161/01.cir.67.6.1174. [DOI] [PubMed] [Google Scholar]
  9. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hirsh P. D., Hillis L. D., Campbell W. B., Firth B. G., Willerson J. T. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 1981 Mar 19;304(12):685–691. doi: 10.1056/NEJM198103193041201. [DOI] [PubMed] [Google Scholar]
  11. Hutton I., Tweddel A. C., Rankin A. C., Walker I. D., Davidson J. F. Effects of dazoxiben on transcardiac thromboxane levels and haemodynamics in coronary heart disease. Br J Clin Pharmacol. 1983;15 (Suppl 1):79S–82S. doi: 10.1111/j.1365-2125.1983.tb02113.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Judkins M. P. Selective coronary arteriography. I. A percutaneous transfemoral technic. Radiology. 1967 Nov;89(5):815–824. doi: 10.1148/89.5.815. [DOI] [PubMed] [Google Scholar]
  13. Kiff P. S., Bergman G., Atkinson L., Jewitt D. E., Westwick J., Kakkar V. V. Haemodynamic and metabolic effects of dazoxiben at rest and during atrial pacing. Br J Clin Pharmacol. 1983;15 (Suppl 1):73S–77S. doi: 10.1111/j.1365-2125.1983.tb02112.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Koch G. G. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics. 1972 Jun;28(2):577–584. [PubMed] [Google Scholar]
  15. Kunkes S. H., Pichard A., Meller J., Gorlin R., Herman M. V., Kupersmith J. Use of the ambulatory ECG to diagnose coronary artery disease. J Electrocardiol. 1980 Oct;13(4):341–346. doi: 10.1016/s0022-0736(80)80085-9. [DOI] [PubMed] [Google Scholar]
  16. Lewis H. D., Jr, Davis J. W., Archibald D. G., Steinke W. E., Smitherman T. C., Doherty J. E., 3rd, Schnaper H. W., LeWinter M. M., Linares E., Pouget J. M. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983 Aug 18;309(7):396–403. doi: 10.1056/NEJM198308183090703. [DOI] [PubMed] [Google Scholar]
  17. Lewy R. I., Smith J. B., Silver M. J., Saia J., Walinsky P., Wiener L. Detection of thromboxane B2 in peripheral blood of patients with Prinzmetal's angina. Prostaglandins Med. 1979 Apr;2(4):243–248. doi: 10.1016/0161-4630(79)90059-4. [DOI] [PubMed] [Google Scholar]
  18. Lewy R. I., Wiener L., Walinsky P., Lefer A. M., Silver M. J., Smith J. B. Thromboxane release during pacing-induced angina pectoris: possible vasoconstrictor influence on the coronary vasculature. Circulation. 1980 Jun;61(6):1165–1171. doi: 10.1161/01.cir.61.6.1165. [DOI] [PubMed] [Google Scholar]
  19. Lumley P., Humphrey P. P. A method for quantitating platelet aggregation and analyzing drug-receptor interactions on platelets in whole blood in vitro. J Pharmacol Methods. 1981 Sep;6(2):153–166. doi: 10.1016/0160-5402(81)90038-3. [DOI] [PubMed] [Google Scholar]
  20. Needleman P., Kulkarni P. S., Raz A. Coronary tone modulation: formation and actions of prostaglandins, endoperoxides, and thromboxanes. Science. 1977 Jan 28;195(4276):409–412. doi: 10.1126/science.831285. [DOI] [PubMed] [Google Scholar]
  21. Reuben S. R., Kuan P., Cairns J., Gyde O. H. Effects of dazoxiben on exercise performance in chronic stable angina. Br J Clin Pharmacol. 1983;15 (Suppl 1):83S–86S. doi: 10.1111/j.1365-2125.1983.tb02114.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Robertson R. M., Robertson D., Roberts L. J., Maas R. L., FitzGerald G. A., Friesinger G. C., Oates J. A. Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials. N Engl J Med. 1981 Apr 23;304(17):998–1003. doi: 10.1056/NEJM198104233041703. [DOI] [PubMed] [Google Scholar]
  23. Tada M., Kuzuya T., Inoue M., Kodama K., Mishima M., Yamada M., Inui M., Abe H. Elevation of thromboxane B2 levels in patients with classic and variant angina Pectoris. Circulation. 1981 Dec;64(6):1107–1115. doi: 10.1161/01.cir.64.6.1107. [DOI] [PubMed] [Google Scholar]
  24. Thaulow E., Dale J., Myhre E. Effects of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease. Am J Cardiol. 1984 May 1;53(9):1255–1258. doi: 10.1016/0002-9149(84)90074-2. [DOI] [PubMed] [Google Scholar]
  25. de Boer A. C., Turpie A. G., Butt R. W., Johnston R. V., Genton E. Platelet release and thromboxane synthesis in symptomatic coronary artery disease. Circulation. 1982 Aug;66(2):327–333. doi: 10.1161/01.cir.66.2.327. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES